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Background: Although cross-sectional studies have suggested a relationship
between proton pump inhibitor (PPI) use and hypomagnesemia, no large-scale
cohort study has been conducted to date. Here, we examined the changes in serum
magnesium levels in response to PPI use. We hypothesized that PPI use might
change the serum magnesium concentration.
Methods: Of the 2,892 patients hospitalized for percutaneous coronary interven-
tion between January 2007 and May 2012, 1,076 patients with normal baseline (1.6–
2.5 mg/dL) and follow-up serum magnesium concentrations were enrolled. These
patients were divided into two groups: the PPI group and the control group.
Results: The mean follow-up period was 9.5172.94 months. The incidence of
hypomagnesemia (o1.6 mg/dL) was 0.4% (3/834) in the PPI group and 0.4% (1/242)
in the control group (P ¼0.904). The change in magnesium levels did not differ
between the two groups, and this result was maintained in the analysis of
covariance after adjusting for confounding factors (P ¼ 0.381). Moreover, magne-
sium levels did not signiﬁcantly differ between the long-term (duration of use Z12
months, n ¼ 71) and short-term PPI groups (duration of use o12 months,
n ¼ 763), and the control group (n ¼ 242; P ¼ 0.620). The effect of PPI use on
change in serum magnesium concentration was affected by the use of multiple
diuretics (0.0170.25 mg/dL; P ¼ 0.025), although a single diuretic use with PPI
did not alter the change in magnesium level (0.1270.27 mg/dL).
Conclusion: Changes in magnesium levels might be subtle after PPI use in patients
with normal baseline magnesium values.
Copyright & 2015. The Korean Society of Nephrology. Published by Elsevier. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).15. The Korean Society of Nep
.org/licenses/by-nc-nd/4.0/).
al Medicine, Soonchun-
nhyang 3gil, Dongnamgu,Introduction
Magnesium is the second most common intracellular cation
and is involved in a wide range of cellular functions, including
protein synthesis, enzymatic reactions, and the regulation of
ion channels. Signiﬁcantly low serum magnesium levels have
been associated with bradycardia, hypotension, seizures,
tetany, and death [1,2].hrology. Published by Elsevier. This is an open access article under the
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They have been associated with a wide variety of side effects
including renal failure, respiratory infections, Clostridium difﬁ-
cile colitis, and hip fractures [3–7]. There have been several
case reports and case series of PPI-induced hypomagnesemia
(PIH) with a wide array of symptoms, including cardiac
arrhythmias and seizures [8–13]. A common characteristic of
PIH might be the long-term use of PPIs (41 year duration) and
the presence of severe hypomagnesemia. If the long-term use
of PPIs could decrease the serum magnesium level, PPI use
might be a risk factor in patients with coronary heart disease.
Serum magnesium levels might be particularly important in
patients with coronary heart disease who are taking PPIs.
Although some cross-sectional studies have suggested that PPI
use could be related with hypomagnesemia [14–17], there was a
lack of causal relation between PPI use and hypomagnesemia.
To address these questions, we examined the change in
serum magnesium level after use of PPI in a retrospective
cohort of 1,076 patients, who underwent percutaneous cor-
onary intervention (PCI) in a tertiary medical center.Methods
Study population
The study population consisted of all patients undergoing
PCI from January 2007 to May 2012 at the Soonchunhyang
University Cheonan Hospital, Korea.
Our exclusion criteria included the following: patients
without follow-up magnesium data, baseline magnesium
o1.6 mg/dL, baseline magnesium 42.5 mg/dL, hemodialysis
patients, estimated glomerular ﬁltration rate (GFR) of
o15 mL/min/1.73 m2, and patients who were prescribed laxa-
tives including magnesium or histamine-2 receptor antagonist.
Baseline magnesium level was measured at admission to
undergo PCI, and follow-up magnesium level was measured
at readmission for follow-up coronary angiography or cardiac
event. During this time, the patients taking PPIs were assignedFigure 1. The ﬂowchart illustrates the patients’ inclusion and exclusion i
inhibitor.to the PPI group. Blood sampling was carried out before the
intravenous ﬂuid therapy.
To investigate PPI use in relation to change in magnesium
levels, patients were divided into groups (Fig. 1). First, patients
were divided into the PPI group and the control group (those
who did not use PPIs). Second, the PPI group was further
divided into the short-term PPI group (duration of use o12
months) and the long-term PPI group (duration of use Z12
months). The Institutional Review Board of Soonchunhyang
University Cheonan Hospital approved this study.
Study variables
To investigate the prescription of PPIs, details on duration of
use and type were obtained. Using a dose conversion factor, a
daily omeprazole equivalent dose was also calculated when the
daily PPI dose was documented. In brief, a 20-mg oral dose of
omeprazole was considered to have an equivalent therapeutic
efﬁcacy to 20 mg esomeprazole, 30 mg lansoprazole, 40 mg
pantoprazole, and 20 mg rabeprazole. PPI intensity was deﬁned
as equivalent dose multiplied by duration (months) of PPI use.
To improve clinical relevance, several covariates of interest
were collected: age, sex, diabetes mellitus, history of diuretics
use, and selected laboratory variables (serum creatinine, cal-
cium, albumin, potassium) obtained at the time of hospital
admission or, if they are missing, within the 1st day of
hospitalization. The GFR was estimated using the Chronic
Kidney Disease Epidemiology Collaboration equation [18].
Statistical analysis
Data are presented as the mean7standard deviation for
continuous variables and frequency (in percent) for the catego-
rical variables. The difference between groups was compared
using the Student t test or analysis of variance for continuous
variables and a Chi-square test for categorical variables. The
effects of PPIs on changes in serum magnesium level were
analyzed using analysis of covariance (ANCOVA), with the PPI
group as the main factor, and adjusting for factors inﬂuencing then this study. PCI, percutaneous coronary intervention; PPI, proton pump
Kidney Res Clin Pract 34 (2015) 98–102100baseline magnesium value. A P value of o0.05 was considered
statistically signiﬁcant. The statistical analysis was performed
using SPSS for Windows version 18.0 (SPSS Inc., Chicago, IL, USA).Table 2. Comparisons of serum magnesium concentration between
PPI group and control group
Control group PPI group Pn P†
Baseline (mg/dL) 2.0370.18 2.0370.18 0.948
Follow-up (mg/dL) 2.0770.21 2.0570.20 0.190
Change (mg/dL) 0.0470.23 0.0270.23 0.269 0.103
n P value by Student t test.
† P value by ANCOVA adjusting for age, sex, baseline GFR, baseline Ca,
use of diuretics, and baseline K.
Values are N, mean7SD.
ANCOVA, analysis of covariance; Ca, calcium; GFR, glomerular ﬁltration
rate; K, potassium; PPI, proton pump inhibitor.Results
Patient baseline characteristics
Of the 2,892 individuals hospitalized for PCI, 1,076 were
enrolled in this study (Fig. 1). All patients were admitted for
coronary heart disease and received PCI. These patients were
followed up to monitor their condition. The mean follow-up
duration was 9.5172.94 months. Among these patients, 834
received PPI agents according to the clinician’s opinion. Table 1
lists the characteristics of the study population. None of the
patients received digoxin. After PCI, all patients were observed
in the outpatient clinic. The baseline magnesium levels did not
differ between the control group (2.0270.18 mg/dL) and the
PPI group (2.0370.18 mg/dL; P ¼ 0.948). There was no differ-
ence in baseline characteristics between the two groups except
for use of potassium-sparing diuretics (Table 1).
Effect of PPI use on serum magnesium
The incidence rate of hypomagnesemia during the follow-up
period was 0.4% (3/834) in the PPI group and 0.4% (1/242) in the
control group (P ¼ 0.904). To investigate PPI use in relation with
change in magnesium level, the ANCOVA test was performed.
After adjusting for baseline magnesium, the results showed that
change in magnesium level was not inﬂuenced by PPI use
(P ¼ 0.179). After ANCOVA adjusting for age, sex, baseline GFR,
baseline calcium, use of diuretics, and baseline potassium, it was
noted that the change in magnesium level was not signiﬁcantly
different between the two groups (P ¼ 0.103; Table 2).
Effect of duration of PPI use on serum magnesium
To investigate the impact of prolonged use of PPIs on serum
magnesium concentration, the PPI group was divided into the
long-term group and the short-term group. The mean duration
of PPI use was 6.3973.20 months in the short-term PPI groupTable 1. Baseline characteristics of the study population
Control group (n
Age (y) 62.39711
Male sex 166 (68.
Diabetes mellitus 81 (33.
Underlying cardiac disease
Angina pectoris 160 (66.
NSTEMI 29 (12.
STEMI 44 (18.
ICMP 9 (3.7
Serum magnesium (mg/dL) 2.0270.1
Serum creatinine (mg/dL) 0.8670.3
eGFR (mL/min/1.73 m2) 88.62720
Serum albumin (g/dL) 4.4070.3
Serum calcium (mg/dL) 9.0370.5
Serum phosphate (mg/dL) 3.3570.8
Serum potassium (mEq/L) 4.1770.4
Use of diuretics during follow-up period 76 (31.
Values are N, mean7SD.
eGFR, estimated glomerular ﬁltration rate; ICMP, ischemic cardiomyopathy
myocardial infarction.and 12.2070.62 months in the long-term PPI group (Po
0.001). Each PPI intensity was 4.4772.92 in the short-term PPI
group and 7.3972.59 in the long-term PPI group (Po0.001).
The use of diuretics was not different between two groups
(26.1% vs. 25.4%, P ¼ 0.875). Based on the comparison of the
short-term and the long-term PPI groups, the change in
magnesium level was not signiﬁcantly different using the
Student t test and ANCOVA with or without adjustment for
confounding factors. Also, when comparing the three groups
(control, long term, short term), the change in magnesium
levels was not signiﬁcantly different (Table 3).
Effect of PPI use with diuretics on serum magnesium
Given the modifying effect of diuretics, we then assessed
whether the type and combined use of multiple diuretics
further inﬂuenced the change in serum magnesium level after
PPI use. As shown in Table 4, the effects of PPI use on change in
serummagnesium level were similar among individuals taking
any type of diuretic agents. The effect of PPI use on change in
serum magnesium level was altered by the use of multiple
diuretics. However, the single diuretic use with PPI did not
inﬂuence the change in magnesium level.
Effect of PPI use according to GFR on serum magnesium
We investigated the effect of PPI use on serum magnesium
in patients with low GFR (i.e., 15–60 mL/min/1.73 m2; n ¼ 116,¼ 242) PPI group (n ¼ 834) P
.00 63.20711.26 0.324
6%) 528 (63.3%) 0.130
5%) 268 (32.1%) 0.696
0.197
1%) 571 (68.5%)
0%) 118 (14.1%)
2%) 130 (15.6%)
%) 15 (1.8%)
8 2.0370.18 0.948
4 0.8470.30 0.415
.02 88.26719.66 0.801
8 4.3770.40 0.211
1 8.9770.56 0.251
0 3.3770.76 0.841
8 4.1670.44 0.925
4%) 218 (26.1%) 0.106
; NSTEMI, non-ST elevation myocardial infarction; STEMI, ST elevation
Table 4. Effect of diuretics on association between PPI use and change in serum magnesium level
Change in serum magnesium level (mg/dL)
Control group PPI group Pn
Loop diuretics (n ¼ 69) 0.0270.23 0.0970.27 0.282n
Thiazide diuretics (n ¼ 82) 0.0170.11 0.0370.22 0.801n
Potassium-sparing diuretics (n ¼ 47) 0.0570.25 0.0370.34 0.431n
Multiple (n ¼ 96) 0.1270.27 0.0170.25 0.025n
Loop þ thiazide 0.1070.42 (n¼2) 0.1070.37 (n¼4) 0.999†
Loop þ potassium sparing 0.1270.20 (n¼15) 0.0370.24 (n¼43) 0.188†
Thiazide þ potassium sparing 0.1070.4 (n¼8) 0.1870.24 (n¼13) 0.151†
More than 3 diuretic agents 0.1770.06 (n¼8) 0.1370.22 (n¼13) 0.054†
n P value by ANCOVA.
† P value by t test.
Values are N, mean7SD.
ANCOVA, analysis of covariance; PPI, proton pump inhibitor.
Table 3. Comparisons of serum magnesium levels in controls, short-term PPI group, and long-term PPI group
Control Short-term PPI use (o12 mo) Long-term PPI use (Z12 mo) Pn P†
Baseline (mg/dL) 2.0370.18 2.0270.18 2.0470.19 0.851
Follow-up (mg/dL) 2.0770.21 2.0570.20 2.0670.17 0.347
Change (mg/dL) 0.0470.23 0.0270.23 0.0370.22 0.540 0.213
n P value by ANOVA
† P value by ANCOVA adjusting for age, sex, baseline GFR, baseline Mg, use of diuretics, and baseline K
Values indicate the mean7SD.
ANCOVA, analysis of covariance; ANOVA, analysis of variance; GFR, glomerular ﬁltration rate; K, potassium; Mg, magnesium; PPI, proton pump
inhibitor.
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sium levels was not signiﬁcantly different after PPI use (con-
trols, 0.0470.27; PPI users, 0.0370.28; P ¼ 0.818).
Furthermore, in patients with GFR 460 mL/min/1.73 m2, the
change in magnesium levels was not signiﬁcantly different
after PPI use (controls, 0.0470.02; PPI users, 0.0270.22;
P ¼ 0.270).Discussion
Several case reports suggested that PPI use could be related
with hypomagnesemia [8,11,12,19,20]. Although these cases
series showed that chronic use of PPIs could be a risk factor,
there was lack of causal relationship to support the premise
that long-standing use of PPIs could be linked with hypomag-
nesemia. In recent years, some cross-sectional studies sup-
ported these ﬁndings. Danziger et al [14] suggested that serum
magnesium concentrations on admission were lower among
patients who were taking both PPIs and diuretics than in
patients without PPI use, as documented in a large sample of
critically ill patients. No such relationship was found among
PPI users who were not taking diuretics. Koulouridis et al [16]
investigated whether there was an association in 402 adults
between hypomagnesemia at the time of hospital admission
and out-of-hospital use of PPIs. They found that out-of-
hospital PPI use was not associated with hypomagnesemia at
the time of hospital admission [16]. Kim retrospectively
studied 112 consecutive patients aged 20 years or older who
were treated with PPIs for Z30 days and whose serum
magnesium levels were available for the PPI treatment period
[17]. This study included only 105 PPI users and 210 nonusers
with matched controls. There was no difference in magnesium
level between the two groups. In the PPI group,hypomagnesemia was observed in 32 patients. However, the
mean magnesium value was 0.76mM (1.85 mg/dL) in the
hypomagnesemia group. No incidence of hypomagnesemia
was observed in the control group. Therefore the authors did
not prove whether PPI itself is a risk factor of hypomagnese-
mia. Previous studies were mostly cross-sectional studies that
did not reveal the causal relationship.
The purpose of our study is to investigate the change in
magnesium level after PPI use. In Korea, regulations allow PPIs
to be prescribed only in hospitals. We showed that PPI use was
not related with change in serum magnesium. In particular, we
showed that the long-term (41 year) use of PPI is not related
with the change in magnesium level. This ﬁnding suggested
that PIH might be not related with duration or dose. We
thought that PIH may be attributed to individual sensitivity
including gene variant. After adjusting for confounding factors,
PPI use was not found to be related with change in serum
magnesium. In our study, concomitant use of diuretics itself
did not alter serum magnesium levels; however, use of multi-
ple diuretics with concomitant use of PPIs decreased the
serum magnesium. This ﬁnding is similar to that of a previous
meta-analysis [21], which showed that PPI use may increase
the risk of hypomagnesemia. However, the authors showed
that, based only on hospitalized patients or 1.7 mg/dL of the
cutoff value, PPI use was not associated with hypomagnese-
mia. Yet, when based on 1.8 mg/dL of the cutoff value, PPI use
increased the risk of hypomagnesemia. Park et al [21] also
demonstrated the signiﬁcant heterogeneity among the
included studies. In our study, we included only hospitalized
patients and the cutoff value is less than 1.6 mg/dL (even
though 1.7 or 1.8 mg/dL of the cutoff value did not inﬂuence
the results; data not shown). We think that heterogeneity
among studies prevented us from reaching a deﬁnite
conclusion.
Kidney Res Clin Pract 34 (2015) 98–102102The mechanism of PIH remains unclear. PPI-induced hypo-
chlorhydria has been postulated [8]. However, there was no
evidence of hypomagnesemia after use of the other antacid.
Some data also suggested that genetic factors might result in
increased susceptibility to PIH. It is unknown if the prolonged use
of PPIs could cause an altered regulation of the transient receptor
potential melastin 6/7 (TRPM6/7), which is an active transcellular
channel present in the gastrointestinal tract and kidneys involved
in driving cations such as magnesium and calcium into the cells
[22,23]. TRPM6/7 mutations are postulated to impair kidney
function and, possibly, also the urinary excretion of magnesium.
TRPM6/7 mutations have been shown in human disease only in
associationwith magnesium urinary wasting or hypomagnesemia
with secondary hypocalcemia, a rare autosomal recessive disorder
characterized by diminished intestinal absorption and increased
renal excretion of magnesium that is uniformly manifested in
early infancy with generalized convulsions, muscle spasms, or
tetany [24]. Further studies should therefore focus on the
individual susceptibility of PIH.
The U.S. Food and Drug administration has issued a warning
that the prolonged use of PPIs may cause low serum magne-
sium levels and recommended obtaining serum magnesium
levels prior to prescribing PPI treatment in patients who are
expected to be using these drugs for a long period. According
to our results, we recommend that serummagnesium levels be
obtained before prescribing PPI treatment in patients who are
expected to use multiple diuretics.
Our study has several limitations. The incidence of hypo-
magnesemia is very small in our study. Hypomagnesemia is a
common entity, occurring in up to 12% of hospitalized patients
[25]. The incidence rises to as high as 60–65% of patients in the
intensive care setting [26]. Previous cross-sectional studies
included only patients admitted to intensive care units [14].
Patients in our study had a less severe condition compared
with patients in previous cross-sectional studies. In conclu-
sion, the change in magnesium level might be subtle after PPI
use in patients with normal baseline magnesium values.Conﬂict of interest
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